IS5479A - Efnasambönd - Google Patents

Efnasambönd

Info

Publication number
IS5479A
IS5479A IS5479A IS5479A IS5479A IS 5479 A IS5479 A IS 5479A IS 5479 A IS5479 A IS 5479A IS 5479 A IS5479 A IS 5479A IS 5479 A IS5479 A IS 5479A
Authority
IS
Iceland
Prior art keywords
compounds
Prior art date
Application number
IS5479A
Other languages
English (en)
Inventor
David Eldred Colin
Michael Kenneth Pennell Andrew
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5479A publication Critical patent/IS5479A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IS5479A 1997-11-08 2000-05-03 Efnasambönd IS5479A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723590.7A GB9723590D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007023 WO1999024451A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Publications (1)

Publication Number Publication Date
IS5479A true IS5479A (is) 2000-05-03

Family

ID=10821761

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5479A IS5479A (is) 1997-11-08 2000-05-03 Efnasambönd

Country Status (27)

Country Link
US (2) US6544960B1 (is)
EP (1) EP1030856B1 (is)
JP (1) JP2001522859A (is)
KR (1) KR20010031878A (is)
CN (1) CN1217952C (is)
AP (1) AP2000001804A0 (is)
AT (1) ATE273989T1 (is)
AU (1) AU763414B2 (is)
BR (1) BR9813989A (is)
CA (1) CA2309202C (is)
DE (1) DE69825779T2 (is)
EA (1) EA003087B1 (is)
EE (1) EE04499B1 (is)
ES (1) ES2222619T3 (is)
GB (1) GB9723590D0 (is)
HR (1) HRP20000277A2 (is)
HU (1) HUP0004102A3 (is)
ID (1) ID24758A (is)
IL (2) IL135966A0 (is)
IS (1) IS5479A (is)
NO (1) NO20002359L (is)
NZ (1) NZ504336A (is)
PL (1) PL340873A1 (is)
SK (1) SK6702000A3 (is)
TR (1) TR200001937T2 (is)
WO (1) WO1999024451A2 (is)
YU (1) YU26800A (is)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
GB9930085D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
GB0221694D0 (en) * 2002-09-18 2002-10-30 Glaxo Group Ltd Compounds
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
KR20050097971A (ko) 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ₁아데노신 수용체의 부분 및 전 작용제
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
DK1641444T3 (en) * 2003-06-02 2016-06-27 Isis Innovation Treatment of muscle fatigue
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
FR2862873A1 (fr) * 2003-12-01 2005-06-03 Pf Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
AU2006320578B2 (en) * 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
DK2240017T3 (da) 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
CN101602786B (zh) * 2008-06-10 2014-04-30 中国医学科学院药物研究所 N6-取代腺苷衍生物、其制法以及药物组合物与用途
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
CN101857622B (zh) * 2009-04-07 2014-12-03 中国医学科学院药物研究所 一种腺苷衍生物及其制备方法和应用
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
CN104382924B (zh) * 2009-12-10 2017-12-22 中国医学科学院药物研究所 N6‑取代腺苷衍生物和n6‑取代腺嘌呤衍生物及其用途
JP2013513551A (ja) * 2009-12-10 2013-04-22 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠，抗うつ，抗痙攣，抗てんかん，抗パーキンソン病と認知証予防・治療の用途
WO2011085361A1 (en) 2010-01-11 2011-07-14 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
US8476247B2 (en) 2010-03-26 2013-07-02 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
AU2013211957B2 (en) 2012-01-26 2017-08-10 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of (2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
DK2914251T3 (da) 2012-11-05 2019-11-04 Us Health Ketonlegemer til beskyttelse af væv mod beskadigelse som følge af ioniseringsstråling
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
BR112015023334B1 (pt) 2013-03-14 2021-05-18 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services processo para produção de (r)-3hidroxibutil (r)-3-hidroxibutirato
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4868160A (en) * 1985-11-06 1989-09-19 Warner-Lambert Company Method of treating psychosis using N6 -substituted -5'-oxidized adenosine analogs
JPH0723394B2 (ja) * 1986-11-27 1995-03-15 日本臓器製薬株式会社 新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
ES2095960T3 (es) * 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
DK62592D0 (is) * 1992-05-14 1992-05-14 Novo Nordisk As
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
JPH07118156A (ja) * 1993-10-26 1995-05-09 Nippon Zoki Pharmaceut Co Ltd アデノシンデアミナーゼ阻害剤
JPH08269083A (ja) * 1995-04-03 1996-10-15 Banyu Pharmaceut Co Ltd Ｎ６−置換アデノシン誘導体
AU2022497A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
AU2022597A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO1999024451A2 (en) 1999-05-20
DE69825779D1 (de) 2004-09-23
BR9813989A (pt) 2000-09-26
CN1217952C (zh) 2005-09-07
EA200000398A1 (ru) 2000-12-25
ID24758A (id) 2000-08-03
NZ504336A (en) 2002-11-26
CA2309202A1 (en) 1999-05-20
GB9723590D0 (en) 1998-01-07
JP2001522859A (ja) 2001-11-20
CA2309202C (en) 2008-06-17
NO20002359D0 (no) 2000-05-05
YU26800A (sh) 2002-12-10
HUP0004102A3 (en) 2002-09-30
AP2000001804A0 (en) 2000-06-30
SK6702000A3 (en) 2001-01-18
EE200000283A (et) 2001-08-15
WO1999024451A3 (en) 1999-08-19
US20030158146A1 (en) 2003-08-21
US6544960B1 (en) 2003-04-08
ATE273989T1 (de) 2004-09-15
HRP20000277A2 (en) 2000-10-31
KR20010031878A (ko) 2001-04-16
AU1666599A (en) 1999-05-31
EP1030856A2 (en) 2000-08-30
EA003087B1 (ru) 2002-12-26
IL135966A0 (en) 2001-05-20
US6740644B2 (en) 2004-05-25
AU763414B2 (en) 2003-07-24
NO20002359L (no) 2000-07-05
IL135966A (en) 2006-06-11
EP1030856B1 (en) 2004-08-18
ES2222619T3 (es) 2005-02-01
DE69825779T2 (de) 2005-08-25
EE04499B1 (et) 2005-06-15
PL340873A1 (en) 2001-03-12
TR200001937T2 (tr) 2000-11-21
HUP0004102A2 (hu) 2001-04-28
CN1285844A (zh) 2001-02-28

Similar Documents

Publication Publication Date Title
PT860428E (pt) Compostos pirimidiona
IS5479A (is) Efnasambönd
IS5478A (is) Efnasambönd
IS5477A (is) Efnasambönd
ID22850A (id) Senyawa-senyawa pirazina
IS5354A (is) Ný efnasambönd
NO994877D0 (no) Kalsilytiske forbindelser
EE200000321A (et) Uudsed ühendid
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
EE9900448A (et) Ühendid
NO995404D0 (no) Forbindelser
EE9900602A (et) Ühendid
ID22983A (id) Senyawa-senyawa fluorometoksimino
IS5211A (is) Efnasambönd
DE69737634D1 (de) Insektizide oxadiazinverbindungen
SE9702775D0 (sv) Novel compounds
ID18388A (id) Senyawa-senyawa heterosiklik
SE9701397D0 (sv) Compounds
ID21202A (id) Senyawa heterosiklik
SE9701964D0 (sv) Compounds
SE9702378D0 (sv) New compounds
SE9703225D0 (sv) new compounds
SE9702535D0 (sv) New compounds
SE9702696D0 (sv) New compounds
SE9701220D0 (sv) New compounds